Phase 2 clinical trial data of voreloxin to be presented at 2010 ASCO Annual Meeting: announces an investment report featuring Sunesis Pharmaceuticals Inc. (Nasdaq:SNSS). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at:

Sunesis Pharmaceuticals Inc. (SNSS) is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. The Company focuses primarily on the development of voreloxin for the treatment of acute myeloid leukemia (AML). It owns global development and commercialization rights to voreloxin and is preparing for the Phase III development of the compound.

Message Board Search for SNSS:

In the report, the analyst notes:

"On April 19, SNSS announced that data from three Phase 2 clinical trials of voreloxin have been accepted for presentation June 7 at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, which runs from June 4 to June 8. The presentations include an oral presentation of final data from the Company's Phase 2 trial of voreloxin in ovarian cancer, as well as poster presentations and discussion sessions of maturing data from its two Phase 2 studies of voreloxin in AML.

"SNSS believes voreloxin represents one of the most promising anticancer compounds in development for the treatment of AML, and the outcomes of the Company's productive meetings with the FDA have provided a clear registration path for voreloxin in this indication. According to CEO Daniel Swisher, the Company is now focused on finalizing preparations for the Phase 3 trial and looks forward to sharing updated data from its fully enrolled Phase 2 AML and ovarian cancer trials at ASCO in June."



The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Study examines the relationship between exclusive human milk consumption and gut microbiota in preterm infants